810 results match your criteria Breast Care[Journal]


Highlights from the San Antonio Breast Cancer Symposium (SABCS) 2019.

Breast Care (Basel) 2020 Apr 14;15(2):192-196. Epub 2020 Feb 14.

Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204834PMC

Immediate Breast Reconstruction.

Breast Care (Basel) 2020 Apr 21;15(2):188-191. Epub 2020 Jan 21.

Department of Breast and Sarcoma Surgery, Centre of Surgical Oncology, National Institute of Oncology, Budapest, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505176DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204885PMC

Factors Influencing the Onset of Neoadjuvant Therapy in Breast Cancer Patients.

Breast Care (Basel) 2020 Apr 29;15(2):182-187. Epub 2019 Aug 29.

Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical School, Homburg, Germany.

Background: Time to treatment onset (TTTO) is critical in breast cancer patients receiving neoadjuvant chemotherapy (NACT). We therefore investigated possible delaying factors of therapy onset.

Methods: All patients were included who qualified for NACT in our hospital from 2015 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204773PMC

Existence of Cervical Discopathy in Non-Cyclic Mastodynia.

Breast Care (Basel) 2020 Apr 19;15(2):178-181. Epub 2019 Jul 19.

Department of General Surgery, Keçioren Training and Research Hospital, University of Medical Sciences, Ankara, Turkey.

Background: Mastodynia is a subjective symptom that impairs the quality of life. It may be directly related with breast disorders. Moreover, a substantial rate is caused of reflective pain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501792DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204837PMC

EVA-Scalp: Evaluation of Patient Satisfaction with a Scalp Cooling Device to Prevent Chemotherapy-Induced Alopecia in Breast Cancer Patients.

Breast Care (Basel) 2020 Apr 25;15(2):171-177. Epub 2019 Jul 25.

Breast Center, Department of Gynecology and Obstetrics and CCC Munich, University of Munich (LMU), Munich, Germany.

Purpose: Scalp cooling (SC) offers a chance to reduce hair loss (HL), but patient satisfaction, the effect on well-being, as well as patient selection criteria have not been sufficiently assessed yet.

Methods: In the EVAScalp trial, SC was offered to 70 breast cancer patients who received chemotherapy between November 2015 and September 2018. For SC, the Paxman-Orbis-II System was used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501393DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204843PMC

Use of Complementary and Alternative Medicine among Young Patients with Breast Cancer.

Breast Care (Basel) 2020 Apr 19;15(2):163-170. Epub 2019 Jul 19.

Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.

Background: Complementary and alternative medicine (CAM) has received increasing attention in Western countries and is especially common among breast cancer (BC) patients. So far, its effectiveness has not been well studied, which is in part due to the contextuality of CAM along with a lack of information of why patients use it.

Objectives: Young BC patients constitute a special patient group regarding clinical characteristics, QOL, and their role in society. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204767PMC

Application of Periareolar Mammaplasty with the Tissue Folding Technique in Breast Reshaping following Polyacrylamide Hydrogel Removal.

Breast Care (Basel) 2020 Apr 11;15(2):157-162. Epub 2019 Jun 11.

Department of General Surgery, Shanghai Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Background: Polyacrylamide hydrogel (PAAG) was used as an injectable implant for augmentation mammoplasty for over 30 years, but its use was ceased due to various related complications. The only way to treat these complications is PAAG removal, but this causes breast ptosis, nipple retraction, breast asymmetry, and skin laxity.

Objectives: This article reports a new technique for breast reshaping after PAAG removal without prosthesis implantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000500879DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204846PMC

Tamoxifen Exposure during Pregnancy: A Systematic Review and Three More Cases.

Breast Care (Basel) 2020 Apr 25;15(2):148-156. Epub 2019 Jul 25.

Fertility and Procreation Unit, Division of Gynecologic Oncology, European Institute of Oncology IRCCS, Milan, Italy.

Tamoxifen is frequently used as adjuvant treatment in premenopausal patients with hormone receptor-positive early breast cancer. According to guidelines, the use of nonhormonal barrier contraception is recommended during tamoxifen treatment and up to 3 months after its interruption prior to attempting conception. Nevertheless, when conception occurs inadvertently during tamoxifen treatment, the effects on the fetus and on the course of pregnancy are still not completely known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204783PMC

Accelerated Partial Breast Irradiation: A New Standard of Care?

Breast Care (Basel) 2020 Apr 21;15(2):136-147. Epub 2020 Feb 21.

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Background: Breast-conserving therapy including lumpectomy and adjuvant whole breast irradiation (WBI) has become the standard therapy for early-stage breast cancer (EBC). Without WBI, the recurrence rate is significantly increased. However, when selecting patients at a low a priori risk of local recurrence only a small breast-cancer-specific mortality benefit, but no overall survival improvement, was detected for WBI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204849PMC

An Update on Regional Nodal Irradiation: Indication, Target Volume Delineation, and Radiotherapy Techniques.

Breast Care (Basel) 2020 Apr 9;15(2):128-135. Epub 2020 Apr 9.

Department of Radiotherapy and Radiation Oncology, University Hospital of the Friedrich Schiller University, Jena, Germany.

Background: Tremendous changes have occurred in the treatment of breast cancer. This paper reviews and unifies the available data on modern axillary management of breast cancer patients with focus on the target volume delineation for regional nodal irradiation according to the most important contouring guidelines, the European Society for Radiotherapy and Oncology (ESTRO) and the Radiation Therapy and Oncology Group (RTOG).

Summary: The use of extensive radiotherapy target volumes (level I, II, III, IV) is probably not necessary for all patients to reproduce the clinical benefit shown in the available randomized trials (EORTC, MA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204856PMC

Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review.

Breast Care (Basel) 2020 Apr 24;15(2):118-126. Epub 2020 Jan 24.

University Hospital Erlangen, Erlangen, Germany.

Background: Gene expression assays are increasingly used for decision-making regarding adjuvant chemotherapy in patients with hormone receptor-positive, HER2-negative breast cancer. There are some clinical situations in which there is also a need for better prognostic and predictive markers to better estimate the amount of benefit from adjuvant radiotherapy. The rising availability of gene expression analyses prompts the question whether their results can also be used to guide clinical decisions regarding adjuvant radiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505656DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204850PMC

Neoadjuvant Radio(chemo)therapy for Breast Cancer: An Old Concept Revisited.

Breast Care (Basel) 2020 Apr 14;15(2):112-117. Epub 2020 Apr 14.

Department of Radiation Oncology, Heinrich Heine University Hospital, Düsseldorf, Germany.

Background: The international standard of care for the treatment of high-risk breast cancer (BC) consists of neoadjuvant chemotherapy (NACT) and surgery followed by adjuvant whole breast/chest wall irradiation. In this setting, the time interval from the start of NACT to the end of radiotherapy (RT) is usually postponed to 6 months or longer. In addition to this, a high percentage of capsular fibrosis may occur when breast implants are irradiated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204855PMC

Adjuvant Radiotherapy for Breast Cancer: More than Meets the Eye.

Authors:
David Krug

Breast Care (Basel) 2020 Apr 15;15(2):109-111. Epub 2020 Apr 15.

Department of Radiation Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204823PMC

Erratum.

Authors:

Breast Care (Basel) 2020 02 4;15(1):102. Epub 2019 Sep 4.

[This corrects the article DOI: 10.1159/000499534.]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098295PMC
February 2020

International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.

Breast Care (Basel) 2020 Feb 10;15(1):82-95. Epub 2020 Feb 10.

Practice for Gynecological Oncology, Cologne, Germany.

The 5th International Consensus Conference for Advanced Breast Cancer (ABC5) took place on November 14-16, 2019, in Lisbon, Portugal. Its aim is to standardize the treatment of advanced breast cancer based on the available evidence and to ensure that all breast cancer patients worldwide receive adequate treatment and access to new therapies. This year, the conference focused on developments and study results in the treatment of patients with hormone receptor-positive/HER2-negative breast cancer as well as precision medicine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505957DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098316PMC
February 2020
0.911 Impact Factor

Highlights from ABC5: Bridging the Gap.

Breast Care (Basel) 2020 Feb 7;15(1):75-81. Epub 2020 Feb 7.

Brustkrebs Deutschland e.V., Hohenbrunn, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505900DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098317PMC
February 2020
0.911 Impact Factor

Agranulocytosis Induced by Tamoxifen in a Breast Cancer Patient.

Breast Care (Basel) 2020 Feb 20;15(1):72-74. Epub 2019 Jun 20.

Oncology Department, Paul Strauss Comprehensive Cancer Center, Strasbourg, France.

Background: The main side effects of tamoxifen are menopausal symptoms. We report a case of agranulocytosis induced by tamoxifen in a 33-year-old woman treated in the adjuvant setting.

Case Presentation: Ten days after the beginning of tamoxifen treatment, the patient complained of asthenia and mucositis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000500708DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098272PMC
February 2020

A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer.

Breast Care (Basel) 2020 Feb 27;15(1):67-71. Epub 2019 May 27.

Comprehensive Cancer Center, General Hospital, Medical University Vienna, Vienna, Austria.

Many analyses of the efficacy of neoadjuvant treatment (NAT) for early breast cancer including a meta-analysis derived from 10 randomized trials came to the conclusion that patients who would achieve pathologic complete response (pCR) following NAT would experience significant improvement in disease-free and overall survival (OS). Thus, pCR was proposed as a surrogate endpoint for OS, with pCR representing a robust prognostic marker for survival at an individual level. In the current analysis, we argue that OS following NAT-induced pCR might have reflected the initial prognosis of patients mainly defined - among other factors - by the initial pathological lymph node status while being largely independent on the type of administrated treatment, thus pleading against the pCR surrogacy hypothesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000500620DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098275PMC
February 2020

Different Treatments for Granulomatous Lobular Mastitis: A Systematic Review and Meta-Analysis.

Breast Care (Basel) 2020 Feb 10;15(1):60-66. Epub 2019 Jul 10.

The First Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.

Objective: Granulomatous lobular mastitis (GLM) is infrequently diagnosed. This study aimed to evaluate the efficacy and safety of managements for GLM in the nonlactation period.

Methods: Publications were retrieved from PubMed, EMBASE, and the Cochrane library on September 10, 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098302PMC
February 2020

Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Breast Cancer: Do We Need a Delayed Image?

Breast Care (Basel) 2020 Feb 29;15(1):55-59. Epub 2019 Apr 29.

Division of Gynecology, Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria.

Background: Sentinel lymph node biopsy has become a standard of care in the treatment of patients with early breast cancer, but clinical guidelines continue to be vague on details of the procedure. We were interested in the results of our 2-day protocol, which includes delayed lymphoscintigraphy at 18 h.

Methods: We reviewed the results of preoperative lymphoscintigrams in patients undergoing surgery for breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098320PMC
February 2020

Adherence and Persistence to Adjuvant Hormonal Therapy in Early-Stage Breast Cancer Patients: A Population-Based Retrospective Cohort Study in Israel.

Breast Care (Basel) 2020 Feb 29;15(1):45-53. Epub 2019 May 29.

Medical Division, Maccabi Healthcare Services, Tel-Aviv, Israel.

Background: Adjuvant hormonal therapy (HT) has been consistently proven to improve multiple outcomes in early breast cancer yet rates of adherence and persistence are variable.

Methods: We retrospectively identified women diagnosed with nonmetastatic breast cancer and initiating HT between January 2000 and December 2007 in a large Israeli health provider. Prescription records including the drug name, date of purchase, and the quantity of pills dispensed were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000500318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098287PMC
February 2020

Clinicopathological Analysis of 90 Cases of Polyacrylamide Hydrogel Injection for Breast Augmentation Including 2 Cases Followed by Breast Cancer.

Breast Care (Basel) 2020 Feb 29;15(1):38-43. Epub 2019 May 29.

Department of Plastic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China.

Background: Although polyacrylamide hydrogel (PAAG) injection for breast augmentation has been prohibited for many years, the long-term complications will be significant for a long period. Few research articles have focused on the clinicopathological analysis.

Materials And Methods: We summarized clinical and pathological features of 90 cases after PAAG-injected breast augmentation, including 2 cases of breast cancer developed following PAAG injection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499832DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098307PMC
February 2020
0.911 Impact Factor

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.

Breast Care (Basel) 2020 Feb 17;15(1):30-37. Epub 2019 Apr 17.

Oncology Unit, ARNAS Civico Palermo, Palermo, Italy.

Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting.

Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495469DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098305PMC
February 2020

Male Breast Cancer Patients' Perspectives on Their Health Care Situation: A Mixed-Methods Study.

Breast Care (Basel) 2020 Feb 22;15(1):22-29. Epub 2019 Aug 22.

German Cancer Society (DKG), Berlin, Germany.

Background: Male breast cancer is rare. No information was available on how male breast cancer patients (MBCPs) experience the health care they receive in Germany in a setting that is tailored to women. The aim of this study was to explore the health care situation of MBCPs from their perspectives. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501956DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098323PMC
February 2020

Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy.

Breast Care (Basel) 2020 Feb 13;15(1):14-20. Epub 2019 Sep 13.

Complex Operative Unit of Breast Surgery, Breast Unit, Oncologic Surgery Department, AOUI, Verona, Italy.

Background: Male breast cancer (MBC) is a rare disease with a rising incidence trend. The major risk factors related to MBC are a positive family history of breast cancer (BC) and / mutations, which indicate a relevant genetic role.

Methods: In this retrospective series, we enrolled 69 male patients presenting with male breast cancer (MBC) between 01/01/1992 and 31/12/2018, and 26 high-risk not-affected men presenting between 01/01/2016 and 31/12/2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501711DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098299PMC
February 2020

Living with Male Breast Cancer: A Qualitative Study of Men's Experiences and Care Needs.

Breast Care (Basel) 2020 Feb 15;15(1):6-12. Epub 2019 Jul 15.

Institute of General Practice, Faculty of Medicine, Christian Albrecht University Kiel, Kiel, Germany.

Background: Male breast cancer (MBC) is rare, and most previous studies limited their focus on clinical aspects of the disease. Psychosocial implications and care needs of MBC patients are poorly understood.

Objectives: The aim of this study is to explore the experiences of men living with breast cancer and to identify supportive care needs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501542DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098286PMC
February 2020

Male Breast Cancer Patients: Lack of Evidence.

Authors:
Isabell Witzel

Breast Care (Basel) 2020 Feb 22;15(1):3-4. Epub 2020 Jan 22.

Breast Center, Department of Gynecology, University Medical Center Hamburg, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098273PMC
February 2020

Post-Neoadjuvant Therapy.

Breast Care (Basel) 2019 Dec 27;14(6):409-413. Epub 2019 Nov 27.

GBG Forschungs GmbH, Neu-Isenburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504661DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940439PMC
December 2019

ACT-FASTER, a Prospective Cohort Study Exploring Treatment Patterns with Fulvestrant and Exemestane in Postmenopausal Patients with Advanced Hormone Receptor-Positive Breast Cancer under Real-Life Conditions in Germany.

Breast Care (Basel) 2019 Dec 9;14(6):401-408. Epub 2019 Feb 9.

Klinik für Gynäkologie und Geburtshilfe, UKSH, Kiel.

Background: Endocrine therapy is recommended for the treatment of postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC).

Methods: ACT-FASTER was a German prospective non-interventional cohort study in postmenopausal women with HR+ ABC receiving fulvestrant 500 mg as first line (1 L), second line (2 L) or third line (3 L), or exemestane (any line) in the real-world palliative setting. Primary study objectives included the effectiveness of fulvestrant according to line of palliative treatment measured by time to progression (TTP), and real-life data on the epidemiology and management of these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493882DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940445PMC
December 2019

Emulsion of Olive Oil and Calcium Hydroxide for the Prevention of Radiation Dermatitis in Hypofractionation Post-Mastectomy Radiotherapy: A Randomized Controlled Trial.

Breast Care (Basel) 2019 Dec 5;14(6):394-400. Epub 2019 Feb 5.

Division of Radiation Oncology.

Background: Most of the patients who have been treated by post-mastectomy radiotherapy (PMRT) experience skin toxicity. There have been few studies on acute radiation dermatitis in breast cancer patients who received hypofractionation PMRT.

Methods: 62 patients were randomized to receive a general skin care regimen with or without the addition of an emulsion of olive oil and calcium hydroxide twice a day, from the initiation of PMRT to 2 weeks after radiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940468PMC
December 2019

Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy.

Breast Care (Basel) 2019 Dec 5;14(6):388-393. Epub 2019 Feb 5.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Center, Peking University Cancer Hospital and Institute, Beijing, China.

Background: We sought to investigate the incremental benefit of trastuzumab in patients with HER2-positive breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT).

Methods: The data of HER2-positive invasive breast cancer patients treated with NACT and achieving pCR were obtained from the institutional database. Patients were categorized according to trastuzumab administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940431PMC
December 2019
0.911 Impact Factor

Comparison of Subpectoral versus Prepectoral Immediate Implant Reconstruction after Skin- and Nipple-Sparing Mastectomy in Breast Cancer Patients: A Retrospective Hospital-Based Cohort Study.

Breast Care (Basel) 2019 Dec 26;14(6):382-387. Epub 2019 Feb 26.

Department of Obstetrics and Gynecology, Faculty of Medicine and University Hospital, University of Cologne, Cologne.

Introduction: Implant-based immediate breast reconstruction (IBR) is a common surgical procedure in breast cancer patients. Comparative analysis concerning the placement of implants is still lacking. Hence, we aimed to analyze pre- versus subpectoral IBR in breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496696DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940459PMC
December 2019

Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems.

Breast Care (Basel) 2019 Dec 24;14(6):373-381. Epub 2019 Sep 24.

Department of Breast Tumours, Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania.

Background: Breast cancer is a cause of morbidity for more than half a million of patients in Europe, resulting in broad societal impacts that affect patients, families, and societies from a human, emotional, economic, and financial perspective. Expenditure for cancer medicines represents one of the principal driving costs of healthcare. The aim of this review is to describe the European policy and regulatory landscape of innovation uptake in breast oncology - with emphasis on value in cancer healthcare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940432PMC
December 2019

Education and Training in Breast Cancer Surgery in Europe.

Breast Care (Basel) 2019 Dec 19;14(6):366-372. Epub 2019 Sep 19.

Guy's Hospital Breast Unit, London, United Kingdom.

Background: The substantial increase in the complexity of breast cancer care in the last few decades has resulted in significant improvements in survival rates and also in the quality of life of breast cancer survivors. However, across Europe there are variations in outcomes and access to the latest techniques. Whilst much of this variance is due to differences in health economies between European member states, training variation may also play a part. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940441PMC
December 2019

European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes.

Breast Care (Basel) 2019 Dec 16;14(6):359-365. Epub 2019 Oct 16.

Breast Surgical Oncology Unit, Clinica Universidad de Navarra, Madrid, Spain.

Background: EUSOMA undertook the commitment of defining the requirements for a specialist breast centre, which has become the reference document for the implementation of breast centres.

Summary: The EUSOMA requirements for a specialist breast centre give clear indications regarding the requisite caseload, dedicated team composition (core and non-core team), organisation, availability of services and equipment throughout the patient pathway, quality control, and application of a multidisciplinary approach. The minimum number of cases is 150 newly diagnosed breast cancer cases per year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940462PMC
December 2019

National Breast Screening Programs across Europe.

Breast Care (Basel) 2019 Dec 25;14(6):354-358. Epub 2019 Oct 25.

Institute of Pathology, Medical University of Graz, Graz, Austria.

Background: Mammography screening programs in Europe revealed a 25-30% breast cancer mortality reduction in women between 50 and 74 years. Early cancer detection and less radical treatment in dedicated multidisciplinary breast centers have improved breast cancer care. Breast population-based screening (persons are individually identified and personally invited to attend screening) is intended to detect breast cancer at an early stage to enable lower mortality rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503715DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940461PMC
December 2019

Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries.

Breast Care (Basel) 2019 Dec 8;14(6):344-353. Epub 2019 Oct 8.

Frontier Science Foundation Hellas, Athens, Greece.

The current status and time trends in breast cancer incidence and survival in the 28 European Union countries (EU-28) is presented here. Rates reported are age adjusted and standardized (ASR). A high incidence and high survival rates were observed in the Northern and Western European countries, with the exception of the Baltic countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940474PMC
December 2019

Towards Harmonisation of Breast Care in Europe.

Breast Care (Basel) 2019 Dec 19;14(6):341-343. Epub 2019 Nov 19.

Medical School, National and Kapodistrian University of Athens, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504526DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940477PMC
December 2019

Recurrence of Primary Breast Angiosarcoma 7 Years after Mastectomy in a 17-Year-Old Woman: A Case Report.

Breast Care (Basel) 2019 Oct 30;14(5):330-333. Epub 2019 Jan 30.

Department of Surgical Oncology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Background: Primary breast angiosarcoma is a rare neoplasm; breast angiosarcoma patients under 20 years old are extremely rare. The prognosis is often poor due to a high relapse rate after surgical resection.

Case Report: We report on a case of a 17-year-old woman suffering from a primary breast angiosarcoma, associated with the local recurrence of a right-breast angiosarcoma 86 months after mastectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493881DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883466PMC
October 2019

Efficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature.

Breast Care (Basel) 2019 Oct 14;14(5):325-328. Epub 2018 Nov 14.

OnkoZentrum Zürich, Zürich, Switzerland.

Background: The cyclin D/cyclin-dependent kinase (CDK)4/6 inhibitor of the CDK4 (INK4)/retinoblastoma (Rb) pathway plays a crucial role in cell cycle progression. Selective CDK4/6 inhibitors specifically target a variety of tumors, with the main focus on hormone receptor(HR)-positive and human epidermal growth factor receptor 2(HER2)-negative breast cancer (BC).

Case Report: We report on the efficacy of neoadjuvant palbociclib and letrozole application in a patient suffering from invasive estrogen receptor (ER)+/HER2- BC and concurrent well-differentiated and dedifferentiated liposarcoma (WD-DDLPS) of the thigh. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493370DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883449PMC
October 2019

Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).

Breast Care (Basel) 2019 Oct 17;14(5):315-324. Epub 2019 Sep 17.

Department of Gynecology and Obstetrics, Interdisciplinary Breast Center, Agaplesion Markus Hospital, Frankfurt/M., Germany.

A German working group of leading breast cancer experts have discussed the votes at the International St. Gallen Consensus Conference in Vienna for the treatment of primary breast cancer with regard to the German AGO (Ar-beitsgemeinschaft Gynäkologische Onkologie) recommendations for clinical practice in Germany. Three of the German breast cancer experts were also members of this year's St. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883436PMC
October 2019
0.911 Impact Factor

Consensus Meeting of Breast Imaging: BI-RADS® and Beyond.

Breast Care (Basel) 2019 Oct 2;14(5):308-314. Epub 2019 Oct 2.

Institute of Clinical Radiology, Medical Faculty and University Hospital Münster, Münster, Germany.

Organizers of medical educational courses are often confronted with questions that are clinically relevant yet trespassing the frontiers of scientifically proven, evidence-based medicine at the point of care. Therefore, since 2007 organizers of breast teaching courses in German language met biannually to find a consensus in clinically relevant questions that have not been definitely answered by science. The questions were prepared during the 3 months before the meeting according to a structured process and finally agreed upon the day before the consensus meeting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503412DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883472PMC
October 2019

Re-Excision Rates in Breast-Conserving Surgery for Invasive Breast Cancer after Neoadjuvant Chemotherapy with and without the Use of a Radiopaque Tissue Transfer and X-ray System.

Breast Care (Basel) 2019 Oct 14;14(5):302-307. Epub 2018 Nov 14.

Klinik für Gynäkologie und Geburtshilfe, Marienhospital Bottrop, Bottrop, Germany.

Background: Significant re-excision rates in breast-conserving surgery (BCS) after neoadjuvant systemic chemotherapy may result from difficulties in defining the surgical target particularly in cases with excellent treatment response. Devices allowing an exact topographic localisation of the lesion in the resected tissue could reduce re-excision rates by optimising the intraoperative detection of involved margins.

Methods: 80 patients with invasive breast cancer receiving BCS after neoadjuvant chemotherapy were included in this non-randomized case-control study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883442PMC
October 2019

Psychological Aspects of Breast Reconstruction after Breast Cancer.

Breast Care (Basel) 2019 Oct 24;14(5):298-301. Epub 2019 Sep 24.

Department of Plastic and Reconstructive Surgery, General Hospital Vienna, Medical University of Vienna, Vienna, Austria.

Even though breast cancer mortality is declining, the diagnosis still poses a huge threat for the affected woman and her close family. Breast cancer surgery, which often includes reconstructive procedures, can help restoring a satisfactory body image. The decision on the type of surgery should always be made together with the patient and should focus on her psychosocial needs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883458PMC
October 2019

Risk Factors for Complications after Skin-Sparing and Nipple-Sparing Mastectomy.

Breast Care (Basel) 2019 Oct 3;14(5):289-296. Epub 2019 Oct 3.

Department of Plastic, Aesthetic, Reconstructive and Hand Surgery, AGAPLESION Diakonieklinikum Rotenburg, Rotenburg (Wümme), Germany.

Introduction: In order to achieve a complication-free breast reconstruction, it is fundamental for each individual patient case to determine preoperatively certain risk factors that might have a negative impact on the postoperative result after skin-sparing (SSM) or nipple-sparing mastectomy (NSM).

Methods: A retrospective study of 39 female breast cancer patients who received SSM or NSM breast reconstruction in our department (time interval: 2010-2015), was performed. The study focus is on determining patient characteristics (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883474PMC
October 2019

Novel Assay Analyzing Tropism between Adipose-Derived Stem Cells and Breast Cancer Cells Reveals a Low Oncogenic Response.

Breast Care (Basel) 2019 Oct 1;14(5):278-287. Epub 2019 Oct 1.

Department of Plastic and Hand Surgery, Technical University Munich, Munich, Germany.

Introduction: In the surgical world of breast cancer reconstruction, fat grafting is commonly viewed as an oncogenic risk. Scientific studies add confusion, given the stark lack of clinical evidence suggesting pro-oncogenic links. Typically, classic migration assays (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503411DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883470PMC
October 2019

Immediate versus Delayed Contralateral Breast Symmetrisation in Breast Reconstruction with Latissimus dorsi Flap: A Comparative Study.

Breast Care (Basel) 2019 Oct 17;14(5):272-276. Epub 2019 Sep 17.

Department of Plastic and General Surgery, Turku University Hospital and the University of Turku, Turku, Finland.

To achieve symmetry in unilateral free flap breast reconstruction often requires a contralateral procedure. There is no evidence in the literature to support the benefit of immediate contralateral breast symmetrisation concomitant to breast reconstruction. We hypothesized that performing a simultaneous contralateral balancing operation at the time as the initial reconstruction might provide immediate symmetry and minimize the frequency of secondary procedures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502769DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883469PMC
October 2019

Standards in Oncoplastic Breast Reconstruction.

Authors:
Christine Radtke

Breast Care (Basel) 2019 Oct 4;14(5):269-270. Epub 2019 Oct 4.

Department of Surgery, Division of Plastic and Reconstructive Surgery, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503680DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883455PMC
October 2019

Promoter Methylation Status of the Retinoic Acid Receptor-Beta 2 Gene in Breast Cancer Patients: A Case Control Study and Systematic Review.

Breast Care (Basel) 2019 Apr 30;14(2):117-123. Epub 2019 Jan 30.

Medical Biology Research Center.

Background: We aimed to determine the promoter methylation status of the retinoic acid receptor-beta 2 gene among breast cancer patients and to review relevant studies in this field in various populations.

Methods: We analyzed 400 samples which comprised blood specimens from 102 breast cancer patients, 102 first-degree female relatives of patients, 100 cancer-free females, 48 breast cancer tissues, and 48 adjacent normal breast tissues from the same patients. The methylation status was determined using methylation-specific polymerase chain reaction (MSP) and DNA sequencing methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489874DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886150PMC